Clinical Trial Update: Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating fruquintinib in combination with tislelizumab followed by radiotherapy for esophageal squamous cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Elunate (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Esophageal Neoplasms | Phase 2 | Status: RECRUITING